Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14071573 | 0.86 | ELANE (0.33) | ELANE | |
| SCHEMBL10564449 | 0.78 | — | — | |
| SCHEMBL23115395 | 0.74 | — | — | |
| SCHEMBL24400280 | 0.68 | — | — | |
| SCHEMBL24137204 | 0.67 | — | — | |
| SCHEMBL7162012 | 0.62 | ALDH1A1 (0.35) | — | |
| SCHEMBL23114366 | 0.59 | PTAFR (0.33) | ELANE | |
| SCHEMBL16863001 | 0.57 | — | — | |
| SCHEMBL12670167 | 0.53 | — | — | |
| SCHEMBL15427202 | 0.49 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097623-B2 | 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics | BIOLIPOX AB (SE) | 2012-01-17 | — | — | US | claimed |
| EP-1841735-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | claimed |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-03-19 | — | — | US | claimed |
| WO-2008009924-A2 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-01-24 | — | — | WO | claimed |
| EP-1841735-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | claimed |
| EP-1841736-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | claimed |
| WO-2006077367-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | claimed |
| WO-2006077366-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | claimed |
| US-11945805-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3383386-B1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-108601766-B | CXCR2 inhibitors | 凯莫森特里克斯股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220009911-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2022-01-13 | — | — | US | disclosed |
| EP-1261328-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030032802-A1 | IL8-receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1261328-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2001064208-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032802-A1 | IL8-receptor antagonists | CXCL8, CCR8, IL18 | ELANE 334/4885 |
| US-20220009911-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | ELANE 86/4885 |
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | ELANE 790/4885 |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | MPO, EPX, PTGES | ELANE 10/4885 |
| US-11820759-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | ELANE 148/4885 |
| US-11945805-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | ELANE 86/4885 |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | ELANE 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.